12:27 EDT UroGen says FDA panel votes against benefit/risk of UGN-102
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma announces outcome of ODAC meeting for UGN-102
- Biotech Alert: Searches spiking for these stocks today
- UroGen Pharma down after FDA posts UGN-102 briefing documents
- TD remains confident in approval after UroGen briefing docs
- UroGen sinks 26% to $7.26 after FDA posts briefing docs for UGN-102